The anti-CXCR4 antibody blocking of the CXCL12/CXCR4 axis was found to significantly reduce TEMs, but not Tie-2– TAMs, recruitment to combretastatin-A4-phosphate (the vascular-disrupting agent)-treated tumour in a murine model [100]. Here, CXCR4 is linked to neoplasm.